We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025. Little has been published about the risks of dehydration for children with chronic kidney disease (CKD). The FDA approved Velphoro (sucroferric oxyhydroxide) for hyperphosphatemia in patients with CKD as young as age 9. Growth impairment in children with CKD of nonglomerular origin is greater than that in children with glomerular CKD. Protocol for trial of daprodustat for treatment for anemia in pediatric patients with CKD stage ≥3. A workshop developed clinical recommendations for the management of pediatric chronic kidney disease. The incidence of pediatric chronic kidney disease (CKD) is low, and there are gaps in the quantity and quality of ... The risk for disease progression among children with chronic kidney disease (CKD) is high, a risk that is modified by ... In the past decade, the population of children living in poverty and lacking healthcare insurance has increased in the ... Due perhaps to unrecognized symptoms and signs of pediatric chronic kidney disease (CKD), there are few data available ... Adult and pediatric patients with chronic kidney disease (CKD) are at high risk for cardiovascular disease-related ... Chronic kidney disease (CKD) is a continuing public health problem. CKD is a progressive disease and children with CKD ... Among adults with chronic kidney disease (AKD), there is an association between diminished cognition, particularly ...